PAR22 COST-EFFECTIVENESS OF RITUXIMAB (MABTHERA) COMPARED WITH ABATACEPT (ORENCIA) FOR THE TREATMENT OF MODERATE/SEVERE RHEUMATOID ARTHRITIS (RA) IN THE UNITED KINGDOM
Abstract
Authors
G Lewis A Kielhorn A Diamantopoulos
G Lewis A Kielhorn A Diamantopoulos
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now